Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL-Reference-Cited by-同舟云学术

Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL

Published:2017-01-24 Issue:2 Volume:20 Page:221-227
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Bryce A H,Alumkal J J,Armstrong A^ORCID,Higano C S,Iversen P,Sternberg C N,Rathkopf D,Loriot Y,de Bono J^ORCID,Tombal B,Abhyankar S,Lin P,Krivoshik A,Phung D,Beer T M

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

http://www.nature.com/articles/pcan201671.pdf

Reference21 articles.

1. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 2013; 19: 3621–3630.

2. Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G et al. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res 2014; 20: 2846–2850.

3. Nelson PS . Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer. J Clin Oncol 2012; 30: 644–646.

4. Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E et al. The evolutionary history of lethal metastatic prostate cancer. Nature 2015; 520: 353–357.

5. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424–433.

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers;Frontiers in Oncology;2024-09-10

2. Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients;European Journal of Nuclear Medicine and Molecular Imaging;2024-08-29

3. Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial;Nature Medicine;2024-08-20

4. Real-world evaluation of access-driven Canadian treatment sequences in progressive prostate cancer (REACTIVATE);CUAJ-CAN UROL ASSOC;2024

5. Evaluating prostate cancer bone metastases response with whole-body MRI: What we know and still need to know;European Radiology;2024-06-20